Post by
fossi_2002 on Feb 21, 2024 9:28am
There has been a complete loss of confidence here
Sometimes it's just hard to bear when you read the cheese that Proph is spouting.
How can you judge the performance of a company or its leader?
Obviously, only on the basis of past performance.
What are these achievements?
The basic business was never developed further, new products were overslept and the sales side was completely neglected.
First a sales manager was hired, then Gilles took over this side again himself. The result is well known. From high profits into the red.
Proph repeatedly praises the cooperation between CZO and Symrise.
An agreement that was praised by many parties turned out to be empty chatter in retrospect.
In contrast to the hymns of praise, one has the feeling that Symrise has stabbed Ceapro in the back with its own development.
And then there is the development of the biotech business. Success rate since the beginning: 0
Of course, development in the biotech sector takes many years. Gilles has proven one thing: he has no foresight.
How long did Proph ignore the failure of the cholesterol-lowering drug and claim that something could still be developed?
How long has the failure of the energy drink been repeatedly referred to as "no failure".
How many delays and failures to meet deadlines and developments did we have to put up with!
Can the loss in value of a share like AEZS be higher?
And now this management wants to demand a further leap of faith from the shareholders.
We are led to believe that AEZS has an enormously high cash position.
However, this is only half the truth.I
n the report on the third quarter, everyone can read that the cash on hand is sufficient for the further development of AEZS's current pipeline until the end of 2025.
How is this cash balance supposed to be sufficient to further develop the pipeline of CZO and PGX in particular?
This is not possible at all under these circumstances.
It is therefore clear that a significant capital increase and thus a further dilution of the shares will and must take place after another reverse stock split.
AEZS is not the solution. Neither in the presentations nor in the individual quarterly reports is there a solution as to how the monthly cash drain can be stopped.
Quarterly losses of over $4m indicate how long the cash position will last.
Biotech stocks were not the stock market's favorite for some time. Nevertheless, the biotech index has developed positively in recent months, reaching its high for the year.
Have the shareholders of CZO and AEZS noticed any of this? NO!
There has been a complete loss of confidence here and this can only be made good if Gilles Gagnon takes his hat off!!!
Comment by
tigerpro on Feb 23, 2024 2:59pm
I mean what fossi_2002 said is very true.